Pharmaceutical composition for the treatment of blood coagulatio

Details Pharmaceutical composition for the treatment of blood coagulatio Pharmaceutical composition for the treatment of blood coagulatio

1997-09-11

2000-01-11

Celsa, Bennett

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 21, 514834, 424101, 424530, 530381, 530384, 530415, 530416, 530412, A61K 3514, A61K 3816, C07K 14745

Patent

active

060136200

ABSTRACT:
The invention relates to a pharmaceutical composition for the treatment of patients with blood coagulation diseases which are caused by coagulation factor deficiency and/or inhibitors of coagulation factors, whereby the composition as a FEIB-activity and is characterized in that it has Factor VIIa and at least one further active ingredient and the activity of at least 10 Factor VIIa units per unit FEIBA. Additionally, the invention comprises a method for the production of the pharmaceutical preparation and its use.

REFERENCES:
patent: 4287180 (1981-09-01), Thomas
patent: 4640834 (1987-02-01), Eibl et al.
patent: 5344918 (1994-09-01), Dazey et al.
Mariani et al., "Contact Activation and Factor VII After the Use of an Activated Prothrombin Complex Concentrate (FEIBA) in Hemophiliacs w/Inhibitors", Thromb. Res. vol. 31, (1983), pp. 475-488.
Teitel, "The Factor VIII Bypassing Activity of Prothrombin Complex Concentrates: the Roles of Factor of VIIa and of Endothelial Cell Tissue Factor", Throm & Hemo., vol. 66, No. 5, (1991), pp. 559-564.
Headner et al., "Clinical Experience with Human Plasma-Derived Factor VIIa in Patients with Hemophilia A and High Titer Inhibitors", Hemostasis, vol. 19, (1989), pp. 335-343.
Vinazzer, "Comparison Between Two Concentrates with Factor VIII Inhibitor Bypassing Activity", Thrombosis Research, vol. 26, (1982), pp. 21-29.
Deijk, "Evaluation of a Coagulation Assay Determining the Activity State of Factor VII in Plasma", Hemostasis, vol. 13, (1983), pp. 192-197.
Morrissey et al., "Quantitation of Activated Factor VII Levels in Plasma Using a Tissue Factor Mutant Selec. Deficient in Promoting Factor VII Activation", Amer. Soc. Hemato., vol. 81, No. 3, (1993) pp. 734-744.
Bradford, "A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding", Anal. Biochem., vol. 72, (1976), pp. 248-254.
Giles et al., "A Canine Model of Hemophilic (Factor VIII:C Deficiency) Bleeding", Blood, vol. 60, No. 3, (1992), pp. 727-730.
Curling, "Albumin Purification by Ion Exchange Chromatography", Methods of Plasma Protein Fractionation, Academic Press, (1980), pp. 77-97.
Sander et al., Folia Haematol 117(4): 581-587 (1990), ISSN 0323-4347.
Wilms et al., Folia Haematol 117(4): 589-593 (1990), ISSN 0323-4347.
H. Vinazzer, Thrombosis Research 26: 21-29 (1982).
Meili et al., Schweiz Med Wochenschr 125: 405-411 (1995).
Research Disclosure 269: 94-95 (Sep. 1986), Great Britain.
Rote Liste 1993.
Wilms et al., Folia Hematol. vol. 117(4) 581-587 and 589-593 (English translation), 1990.

Affiliated with

Also associated with

Rating

Pharmaceutical composition for the treatment of blood coagulatio does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical composition for the treatment of blood coagulatio, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition for the treatment of blood coagulatio will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1462386